Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

about

Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

Item

http://www.wikidata.org/entity/Q58727285

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@en

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@nl

type

Item

label

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@en

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@nl

prefLabel

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@en

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@nl

P1476

Discovery of the Novel Entecav ...... Integrated Genotypic Analysis

@en

P2093

Alexandra Thiry

http://www.w3.org/2001/XMLSchema#string

Dennis Hernandez

http://www.w3.org/2001/XMLSchema#string

Fiona McPhee

http://www.w3.org/2001/XMLSchema#string

Karen Ericson

http://www.w3.org/2001/XMLSchema#string

Nannan Zhou

http://www.w3.org/2001/XMLSchema#string

Paul J Falk

http://www.w3.org/2001/XMLSchema#string

Ronald E Rose

http://www.w3.org/2001/XMLSchema#string

P2860

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

AASLD guidelines for treatment of chronic hepatitis B.

Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro

Impact of therapy on the long-term outcome of chronic hepatitis B.

Reversibility of hepatitis B virus cirrhosis after therapy: who and why?

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

P304

1123-1135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP4.1231

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30202825

http://www.w3.org/2001/XMLSchema#string

P932

6128232

http://www.w3.org/2001/XMLSchema#string